title: Rituximab in refractory myasthenia gravis: a prospective, open-label study with long-term follow-up.
abstract: We examined the clinical effectiveness of rituximab in fourteen patients with refractory myasthenia gravis (MG). Manual muscle testing (MMT) score was recorded at baseline and followed during the course of the study. Steroid dose, frequency of intravenous immunoglobulin (IVIG) infusions, and plasma exchange (PLEX) were also monitored throughout the duration of the study. All patients responded dramatically to rituximab, as measured by a change in MMT score, prednisone dose, or the frequency of IVIG infusions or PLEX. Rituximab appears safe and effective for the treatment of refractory MG. It should be considered as a therapeutic option in refractory patients.
authors.affiliation: Department of Medicine (Neurology) University of Alberta Edmonton Alberta Canada T6G 2G3.
authors.forename: Dustin
authors.initials: D
authors.lastname: Anderson
authors.affiliation: Department of Medicine (Neurology) University of Alberta Edmonton Alberta Canada T6G 2G3.
authors.forename: Cecile
authors.initials: C
authors.lastname: Phan
authors.affiliation: Department of Medicine (Neurology) University of Alberta Edmonton Alberta Canada T6G 2G3.
authors.forename: Wendy S
authors.initials: WS
authors.lastname: Johnston
authors.affiliation: Department of Medicine (Neurology) University of Alberta Edmonton Alberta Canada T6G 2G3.
authors.forename: Zaeem A
authors.initials: ZA
authors.lastname: Siddiqi